Alterations of the gut microbiota in patients with immunoglobulin light chain amyloidosis.
AL amyloidosis
amyloid
gut dysbiosis
gut microbiota
immunoglobulin light chain amyloidosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
20
06
2022
accepted:
28
09
2022
entrez:
7
11
2022
pubmed:
8
11
2022
medline:
9
11
2022
Statut:
epublish
Résumé
Emerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light chain (AL) amyloidosis. To characterize the gut microbiota in patients with AL amyloidosis, we collected fecal samples from patients with AL amyloidosis (n=27) and age-, gender-, and BMI-matched healthy controls (n=27), and conducted 16S rRNA MiSeq sequencing and amplicon sequence variants (ASV)-based analysis. There were significant differences in gut microbial communities between the two groups. At the phylum level, the abundance of For the first time, we demonstrated the alterations of gut microbiota in AL amyloidosis and successfully established and validated the microbial-based diagnostic model, which boosted more studies about microbe-based strategies for diagnosis and treatment in patients with AL amyloidosis in the future.
Sections du résumé
Background
Emerging evidence revealed that gut microbial dysbiosis is implicated in the development of plasma cell dyscrasias and amyloid deposition diseases, but no data are available on the relationship between gut microbiota and immunoglobulin light chain (AL) amyloidosis.
Methods
To characterize the gut microbiota in patients with AL amyloidosis, we collected fecal samples from patients with AL amyloidosis (n=27) and age-, gender-, and BMI-matched healthy controls (n=27), and conducted 16S rRNA MiSeq sequencing and amplicon sequence variants (ASV)-based analysis.
Results
There were significant differences in gut microbial communities between the two groups. At the phylum level, the abundance of
Conclusions
For the first time, we demonstrated the alterations of gut microbiota in AL amyloidosis and successfully established and validated the microbial-based diagnostic model, which boosted more studies about microbe-based strategies for diagnosis and treatment in patients with AL amyloidosis in the future.
Identifiants
pubmed: 36341382
doi: 10.3389/fimmu.2022.973760
pmc: PMC9628213
doi:
Substances chimiques
RNA, Ribosomal, 16S
0
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
973760Informations de copyright
Copyright © 2022 Yan, Zhao, Ning, Qin, Xing, Wang, Jia, Huang, Ma, Lei, Zhou, Yu, Zhang, Guo and Sun.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Am J Hematol. 2020 Jul;95(7):848-860
pubmed: 32267020
Mayo Clin Proc. 2019 Mar;94(3):465-471
pubmed: 30713046
Appl Physiol Nutr Metab. 2016 Jun;41(6):640-8
pubmed: 27218680
Nat Commun. 2018 Dec 3;9(1):4832
pubmed: 30510245
Environ Microbiol. 2007 Dec;9(12):3077-90
pubmed: 17991035
Neurobiol Aging. 2017 Jan;49:60-68
pubmed: 27776263
Sci Rep. 2017 Feb 08;7:41802
pubmed: 28176819
Genome Biol. 2011 Jun 24;12(6):R60
pubmed: 21702898
Biomed Res Int. 2017;2017:3796359
pubmed: 28497047
Sci Rep. 2017 Oct 19;7(1):13537
pubmed: 29051531
JAMA. 1992 Nov 25;268(20):2946-51
pubmed: 1433713
Front Cell Infect Microbiol. 2020 Oct 20;10:557368
pubmed: 33194798
PLoS One. 2009 Jun 09;4(6):e5842
pubmed: 19513118
Crit Rev Food Sci Nutr. 2019;59(19):3227-3236
pubmed: 30373382
Appl Environ Microbiol. 2011 Dec;77(24):8775-83
pubmed: 22003027
Blood Adv. 2019 Jul 9;3(13):2040-2044
pubmed: 31289031
J Clin Oncol. 2012 Dec 20;30(36):4541-9
pubmed: 23091105
Dig Liver Dis. 2018 Jul;50(7):635-639
pubmed: 29650468
Gastroenterol Clin North Am. 1998 Sep;27(3):595-614, vi
pubmed: 9891699
Annu Rev Pathol. 2015;10:321-44
pubmed: 25387054
Front Aging Neurosci. 2016 Nov 10;8:256
pubmed: 27891089
Gastroenterol Res Pract. 2016;2016:4953120
pubmed: 26880890
J Clin Oncol. 2020 Oct 1;38(28):3252-3260
pubmed: 32730181
J Alzheimers Dis. 2014;39(1):169-79
pubmed: 24150108
Nat Biotechnol. 2020 Jun;38(6):685-688
pubmed: 32483366
Am J Hematol. 2005 Aug;79(4):319-28
pubmed: 16044444
Blood. 2021 Mar 18;137(11):1527-1537
pubmed: 33512409
JPEN J Parenter Enteral Nutr. 2012 Jan;36(1 Suppl):106S-17S
pubmed: 22237870
Curr Neurol Neurosci Rep. 2017 Oct 17;17(12):94
pubmed: 29039142
Ann Rheum Dis. 2019 Oct;78(10):1398-1404
pubmed: 31377728
Blood Cancer J. 2021 May 15;11(5):90
pubmed: 33993188
J Microbiol Biotechnol. 2020 Dec 28;30(12):1793-1800
pubmed: 33144551
Benef Microbes. 2017 Aug 24;8(4):557-562
pubmed: 28618864
BMC Gastroenterol. 2010 Nov 10;10:133
pubmed: 21067563
Med Sci Monit. 2019 Nov 03;25:8269-8280
pubmed: 31678982
J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
pubmed: 18840817
PLoS One. 2013 Oct 24;8(10):e76520
pubmed: 24204633
N Engl J Med. 2021 Jul 1;385(1):46-58
pubmed: 34192431
N Engl J Med. 2003 Aug 7;349(6):583-96
pubmed: 12904524
Amyloid. 2021 Mar;28(1):1-2
pubmed: 33410355
Proc Natl Acad Sci U S A. 2005 Apr 26;102(17):6098-102
pubmed: 15829582
Arthritis Rheumatol. 2016 Dec;68(12):2878-2888
pubmed: 27337150
Behav Brain Res. 2012 Apr 1;229(1):176-84
pubmed: 22249135
J Clin Oncol. 2012 Mar 20;30(9):989-95
pubmed: 22331953
Nature. 2016 Jun 08;534(7606):213-7
pubmed: 27279214
Microbiome. 2020 May 28;8(1):74
pubmed: 32466801